The FTC's Concerns About Amgen's Deal With Horizon

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Amgen is already a significant market player that has a very strong position vis-a-vis some of the intermediaries in the drug prescription industry. Amgen said that it was disappointed with this decision, that it remains committed to completing the deal. Both companies both said that they would work with the courts to try and close the deal by mid-December.

The Federal Trade Commission sued to block the biotechnology company Amgen’s $28.3bn deal to acquire Horizon Therapeutics, Italy is struggling to spend €200bn in EU Covid recovery funds, and Ukraine said it repelled an unprecedented barrage of Russian missiles over Kyiv.

Mentioned in this podcast:

FTC warns of ‘rampant’ pharma consolidation as it targets $28bn Amgen deal

Italy overhauls plans for €200bn in EU Covid recovery funds

Ukraine says it repelled ‘exceptional’ barrage of Russian missiles

The FT News Briefing is produced by Fiona Symon, Sonja Hutson and Marc Filippino. The show’s editor is Jess Smith. Additional help by Katie McMurran, Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Topher Forhecz is the FT’s executive producer. The FT’s global head of audio is Cheryl Brumley. The show’s theme song is by Metaphor Music.

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.